Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 17/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 17/20 | 0.45 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727222 | 0.90 | RAPGEF3 (0.56) | PRMT5WDR77RAPGEF3 | |
| SCHEMBL23351431 | 0.90 | RAPGEF3 (0.56) | PRMT5WDR77RAPGEF3 | |
| SCHEMBL1595241 | 0.90 | RAPGEF3 (0.56) | PRMT5WDR77RAPGEF3 | |
| SCHEMBL3285873 | 0.88 | PRMT5 (0.36) | PRMT5WDR77RAPGEF3PDE4APDE4B | |
| SCHEMBL1740225 | 0.85 | RAPGEF3 (0.39) | PRMT5WDR77RAPGEF3PDE4APDE4B | |
| SCHEMBL17889822 | 0.85 | PDE4A (0.56) | RAPGEF3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1801703 | 0.85 | PDE4A (0.56) | RAPGEF3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29792990 | 0.85 | PDE4A (0.56) | RAPGEF3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16871701 | 0.85 | PDE4A (0.56) | RAPGEF3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14010194 | 0.83 | ADK (0.43) | PRMT5WDR77RAPGEF3PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-12-09 | — | — | US | disclosed |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-12-09 | — | — | US | disclosed |
| US-7713941-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-05-11 | — | — | US | disclosed |
| US-7713941-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-05-11 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | PRMT5 3776/4885WDR77 907/4885RAPGEF3 853/4885 |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | NME1, NME2, NTPCR | PRMT5 3874/4885WDR77 1130/4885RAPGEF3 1924/4885 |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | PRMT5 3776/4885WDR77 907/4885RAPGEF3 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.